INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 55 filers reported holding INOZYME PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,406,916 | -12.9% | 2,239,742 | +15.5% | 0.00% | – |
Q2 2023 | $10,803,906 | +317.9% | 1,939,660 | +329.9% | 0.00% | – |
Q1 2023 | $2,585,335 | +477.7% | 451,193 | +5.9% | 0.00% | – |
Q4 2022 | $447,535 | -61.0% | 426,224 | -0.5% | 0.00% | – |
Q3 2022 | $1,148,000 | -44.1% | 428,431 | -0.5% | 0.00% | – |
Q2 2022 | $2,054,000 | -42.8% | 430,520 | -51.0% | 0.00% | – |
Q1 2022 | $3,593,000 | -37.1% | 878,400 | +4.9% | 0.00% | – |
Q4 2021 | $5,708,000 | -45.3% | 836,998 | -7.1% | 0.00% | – |
Q3 2021 | $10,439,000 | -31.9% | 900,719 | +0.1% | 0.00% | – |
Q2 2021 | $15,335,000 | -10.1% | 899,873 | +4.4% | 0.00% | -100.0% |
Q1 2021 | $17,061,000 | +31.1% | 861,683 | +36.6% | 0.00% | – |
Q4 2020 | $13,018,000 | -1.1% | 630,751 | +25.9% | 0.00% | – |
Q3 2020 | $13,169,000 | – | 500,934 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
Knott David M Jr | 454,008 | $1,907 | 0.73% |
Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |